Patient Square Capital LP increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,480,000 shares of the company's stock after acquiring an additional 251,535 shares during the quarter. Roivant Sciences makes up 55.2% of Patient Square Capital LP's portfolio, making the stock its biggest position. Patient Square Capital LP owned 1.71% of Roivant Sciences worth $147,638,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Roivant Sciences in the 4th quarter worth $39,000. GAMMA Investing LLC lifted its position in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after buying an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after acquiring an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after acquiring an additional 3,426 shares in the last quarter. 64.76% of the stock is owned by institutional investors.
Insider Buying and Selling at Roivant Sciences
In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,551,654.85. The trade was a 10.03% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,223,959 shares of company stock worth $13,420,035. 7.90% of the stock is owned by insiders.
Roivant Sciences Price Performance
Shares of NASDAQ:ROIV traded down $0.02 during midday trading on Monday, reaching $10.78. 1,158,004 shares of the company's stock were exchanged, compared to its average volume of 5,574,635. The stock has a market cap of $7.69 billion, a price-to-earnings ratio of -71.83 and a beta of 1.23. The firm's 50 day simple moving average is $10.51 and its two-hundred day simple moving average is $11.07. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06.
Analyst Ratings Changes
A number of research analysts have recently issued reports on ROIV shares. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Read Our Latest Research Report on ROIV
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
